Track topics on Twitter Track topics that are important to you
Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth articles that have been published worldwide.
We have published hundreds of Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth news stories on BioPortfolio along with dozens of Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth Clinical Trials and PubMed Articles about Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth Companies in our database. You can also find out about relevant Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth Drugs and Medications on this site too.
Atopic dermatitis is associated with substantial patient and caregiver burden. Currently available treatments for atopic dermatitis are inadequate or contraindicated for some patients. Abrocitinib (PF-04965842) is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of atopic dermatitis.
Atopic dermatitis (AD) is associated with altered skin barrier, microbiome, and immune dysregulation that may increase risk of skin infections.
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease, which is caused by several genetic, immunological, and environmental factors. In addition to skin manifestations, AD is associated with an increased risk of depression and suicidal ideation. Furthermore, this association is underappreciated and therefore insufficiently studied.
Atopic dermatitis is one of the most common inflammatory dermatoses in children and adults. The disorder is associated with significant worsening of quality of life. Due to the frequently suggested pathogenetic relationship with atopic dermatitis, immunoglobulin E seems to be an adequate indicator of the disease.
Parental history of atopic disease is a well-established risk factor for development of atopic dermatitis (AD), but several aspects of this association remain unclear.
Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of moderate-to-severe atopic dermatitis. It is a relatively new drug, and whether it is efficacious for other diseases in dermatology is an area of increasing interest. We searched the literature and ClinicalTrials.gov database for uses of dupilumab beyond atopic dermatitis in dermatology and for ongoing studies on new uses for dupilumab. Off-label reports identified described use of dupilumab for several different de...
Atopic dermatitis (AD) is a chronic skin disease that affects 5-20% of children. This disease compromises the quality of life. Omalizumab offers a promising role in the treatment of severe atopic dermatitis.
Lichen planus-like atopic dermatitis clinically mimics lichen planus and can pose a diagnostic challenge. We report a case of a 55-year-old African American woman who developed intensely pruritic papules and plaques on bilateral hands. Histological examination demonstrated acute spongiotic dermatitis with lymphocyte exocytosis into the epidermis. Taken together, a diagnosis of lichen planus-like atopic dermatitis was made. This case serves to highlight that lichen planus-like atopic dermatitis can develop o...
Our understanding of the mechanisms underlying atopic dermatitis has been instrumental in the development of novel pharmacological agents. Worldwide, more than seventy companies are currently developing at least one new drug for the treatment of atopic dermatitis. Based on our current understanding of the pathophysiology of the disease, the present review article highlights the most important novel therapeutic strategies.
SCORing for Atopic Dermatitis (SCORAD) is a tool developed by the European Task Force on Atopic Dermatitis which is used by physicians to assess atopic dermatitis (AD) severity during consultations with their patients. Patient-Oriented SCORAD (PO-SCORAD) is a self-assessment tool for use by patients which has been validated in a study performed in European countries. However, there is currently no adapted tool for evaluating AD severity in black skin.
There is debate whether psoriasis and atopic dermatitis (AD) belong to the same disease spectrum.
Allergic contact dermatitis (ACD) has become more frequent in children. The prevalence of contact sensitization varies with respect to age, sex, and geographic localization.
Atopic dermatitis (AD) is one of the most common inflammatory skin diseases in the western world. Multiple causes have been implicated in the pathogenesis of atopic dermatitis, however in the past years many studies have highlighted the pathogenic role played by abnormal skin barrier in patients with AD. Impaired skin barriers facilitate the penetration of environmental agents/allergens into the skin with resultant chronic inflammation and atopic march. Many components of the epidermal barrier are impaired ...
Dry skin, associated with increased transepidermal water loss (TEWL), is found to precede atopic dermatitis (AD) in childhood.
Epidemiological studies indicate that gene-environment interactions play a role in atopic dermatitis.
Interleukin 32 (IL-32) is a novel cytokine involved in many inflammatory diseases. However, the role of IL-32γ, an isotype of IL-32, in atopic dermatitis has not been reported.
The optimal approaches for monitoring sleep disturbances in adults with atopic dermatitis (AD) is not established. Multiple patient-reported outcome measures for AD and itch have sleep-related items. These items have not been validated previously.
The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD).
Atopic dermatitis is a chronic inflammatory skin disease characterized by pruritic skin lesions.
Atopic dermatitis (AD) is a common chronic illness that has been associated with variation in the filaggrin gene (FLG). Four variants are most often evaluated.
The circulating immune phenotype was defined in adults and young children with early atopic dermatitis/AD, but chronologic changes in blood of AD infants and children through adolescence have not been explored.